These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 15269308)

  • 21. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
    Shiroiwa T; Fukuda T; Tsutani K
    Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales.
    Tappenden P; Jones R; Paisley S; Carroll C
    Eur J Cancer; 2007 Nov; 43(17):2487-94. PubMed ID: 17910914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Our experience of the treatment with cetuximab for unresectable advanced colorectal cancer].
    Yokomizo H; Yoshimatsu K; Osawa G; Matsumoto A; Otani T; Yano Y; Itagaki H; Fujimoto T; Umehara A; Ogawa K
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2249-51. PubMed ID: 21224537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
    Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
    N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reader comments on the cost of cancer care.
    Toftbagen C
    Clin J Oncol Nurs; 2006 Feb; 10(1):15; author reply 15-6. PubMed ID: 16482722
    [No Abstract]   [Full Text] [Related]  

  • 26. Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: a case report.
    Berretta M; Martellotta F; Simonelli C; Di Benedetto F; De Ruvo N; Drigo A; Bearz A; Spina M; Zanet E; Berretta S; Tirelli U
    J Chemother; 2007 Jun; 19(3):343-6. PubMed ID: 17594933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New treatments for colorectal cancer.
    FDA Consum; 2004; 38(3):17. PubMed ID: 15218840
    [No Abstract]   [Full Text] [Related]  

  • 28. Cetuximab (erbitux).
    Bou-Assaly W; Mukherji S
    AJNR Am J Neuroradiol; 2010 Apr; 31(4):626-7. PubMed ID: 20167650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Challenges and opportunities for use of cost-effectiveness analysis.
    Yabroff KR; Schrag D
    J Natl Cancer Inst; 2009 Sep; 101(17):1161-3. PubMed ID: 19666852
    [No Abstract]   [Full Text] [Related]  

  • 30. Two steps forward in the treatment of colorectal cancer.
    Mayer RJ
    N Engl J Med; 2004 Jun; 350(23):2406-8. PubMed ID: 15175443
    [No Abstract]   [Full Text] [Related]  

  • 31. Erbitux trial flawed from the beginning, committee finds.
    Randal J
    J Natl Cancer Inst; 2002 Dec; 94(24):1824-5. PubMed ID: 12488469
    [No Abstract]   [Full Text] [Related]  

  • 32. Progress in the development of novel treatments for colorectal cancer.
    Hoff PM; Pazdur R
    Oncology (Williston Park); 2004 May; 18(6):705-8. PubMed ID: 15214591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
    Saltz LB; Lenz HJ; Kindler HL; Hochster HS; Wadler S; Hoff PM; Kemeny NE; Hollywood EM; Gonen M; Quinones M; Morse M; Chen HX
    J Clin Oncol; 2007 Oct; 25(29):4557-61. PubMed ID: 17876013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world cost analysis of chemotherapy for colorectal cancer in Japan: detailed costs of various regimens during the entire course of chemotherapy.
    Yajima S; Shimizu H; Sakamaki H; Ikeda S; Ikegami N; Murayama JI
    BMC Health Serv Res; 2016 Jan; 16():2. PubMed ID: 26728154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alternate statistical tools and limitations in genetic marker association studies in single-arm drug cancer trials.
    Owzar K
    J Clin Oncol; 2008 Mar; 26(9):1400-1. PubMed ID: 18349389
    [No Abstract]   [Full Text] [Related]  

  • 36. [Cetuximab].
    Takiuchi H
    Gan To Kagaku Ryoho; 2007 Aug; 34(8):1192-5. PubMed ID: 17687200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
    Scartozzi M; Bearzi I; Pierantoni C; Mandolesi A; Loupakis F; Zaniboni A; Catalano V; Quadri A; Zorzi F; Berardi R; Biscotti T; Labianca R; Falcone A; Cascinu S
    J Clin Oncol; 2007 Sep; 25(25):3930-5. PubMed ID: 17761976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract.
    Mahtani RL; Macdonald JS
    Oncologist; 2008 Jan; 13(1):39-50. PubMed ID: 18245011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer.
    Lee D
    Clin Colorectal Cancer; 2004 Sep; 4(3):159-62. PubMed ID: 15377399
    [No Abstract]   [Full Text] [Related]  

  • 40. Two new drugs for colon cancer.
    Med Lett Drugs Ther; 2004 Jun; 46(1184):46-8. PubMed ID: 15184808
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.